Visus Therapeutics Expands Ophthalmic Drug Development Portfolio With Acquisition of ViewPoint Therapeutics’ Assets
SEATTLE--(BUSINESS WIRE)-- #presbyopia--Visus Therapeutics Inc. expanded its pipeline via the acquisition of all patents and other assets of ViewPoint Therapeutics, Inc.